Psychiatrist testifies she has no regrets over treatment of Diego Maradona
She blamed the private medical company for the deficiencies in his home care.
Maradona had surgery for a haematoma which formed between his skull and brain and stayed in intensive care at Los Olivos clinic between November 4 and 11 2020.
He was sent to recover to a private home where he died on November 25 at the age of 60.
'I acted convinced that what I was doing was best for the patient,' said the psychiatrist on Thursday, the first of the defendants to testify in the courts of San Isidro, a northern suburb of Buenos Aires. 'In my role, I did what I could and even more.'
Cosachov was part of Maradona's medical team during the final stages of his life, along with neurosurgeon Leopoldo Luque and psychologist Carlos Diaz.
The three are on trial with doctors Nancy Forlini and Pedro Di Spagna, Mariano Perroni, a representative of the company that provided the nursing service, and nurse Ricardo Almiron.
Maradona died in a rented house in Tigre, a northern suburb of Buenos Aires.
Cosachov broke down in tears twice during her testimony, once when the presiding judge asked her what she thought happened to Maradona, to which she responded simply: 'I don't know'.
Three judges will decide whether those charged are guilty of manslaughter. The maximum jail time for those sentenced is 25 years.
According to the prosecution, the accused professionals did not provide adequate medical care.
'We were all in agreement for home hospitalisation,' the psychiatrist stated, referring to Maradona's daughters, his sisters, his ex-wife, and the company's doctors.
'Involuntary hospitalisation was also considered, but the family didn't want that, and home hospitalisation was the only option.'
According to the testimony of the director of the clinic where Maradona had surgery, the soccer star requested alcohol during the post-operative period, and was difficult to deal with.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 hours ago
- Medscape
Rivaroxaban or Combo Therapy: A Winner for All Ages?
TOPLINE: In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy reduced the risks for major cardiovascular events (MACE) and major bleeding across all adult age groups. METHODOLOGY: Researchers performed a post hoc analysis of data from the AFIRE trial, conducted in Japan, to assess the age-stratified effects of rivaroxaban monotherapy vs treatment with rivaroxaban plus an antiplatelet agent. The analysis included 2215 patients (mean age, 74.3 years; 79.1% men) with AF and stable CAD more than 1 year after revascularization or angiographically confirmed CAD that did not need revascularization. Patients were randomly assigned to 10 mg or 15 mg of rivaroxaban monotherapy, depending on creatinine clearance, or combination therapy involving rivaroxaban plus aspirin or a P2Y12 inhibitor (at the physician's discretion). The patients were stratified into four age groups: younger than 70 years, 70-74 years, 75-79 years, and 80 years or older. The primary efficacy endpoint was MACE, defined as a composite of stroke, myocardial infarction, systemic embolism, unstable angina requiring revascularization, or death; the primary safety endpoint was major bleeding. The patients were followed for up to 45 months. TAKEAWAY: Across the age spectrum, rivaroxaban alone matched combination therapy for reducing the risks for MACE and major bleeding. However, rivaroxaban monotherapy, compared with combination therapy, was associated with a more pronounced reduction in the risk for MACE among patients aged 80 years or older (hazard ratio [HR], 0.61; 95% CI, 0.40-0.93) and a more pronounced reduction in the risk for major bleeding among those younger than 70 years (HR, 0.23; 95% CI, 0.06-0.79). IN PRACTICE: 'Although the present study did not clarify the factors involved, it is important to reaffirm that rivaroxaban monotherapy effectively reduces net adverse clinical events, which comprehensively include both thrombotic and hemorrhagic events, across a wide age range, even in older patients,' the researchers reported. SOURCE: This study was led by Junichi Yamaguchi, MD, PhD, of the Department of Cardiology at Tokyo Women's Medical University in Tokyo, Japan. It was published online on August 13, 2025, in JAMA Cardiology. LIMITATIONS: The open-label design of the trial may have introduced bias. As a post hoc analysis, this study was underpowered, and differences between the two arms may have been missed due to small sample size. The antiplatelet agent was chosen by the treating physician and was not standardized. DISCLOSURES: This study received support from the Japan Cardiovascular Research Foundation through a contract with Bayer Yakuhin, Ltd. Several authors reported receiving grants, personal fees, and endowments from multiple sources, including Bayer, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Abbott, among others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
2 days ago
- Medscape
New Tool Guides Blood Cancer Txs For Patients 60+
TOPLINE: A novel Comprehensive Health Assessment Risk Model (CHARM) incorporating seven health variables effectively predicts nonrelapse mortality and survival in allogeneic hematopoietic cell transplantation recipients aged at least 60 years. The model stratified 1-year nonrelapse mortality rates from 8.1% to 23.3% across risk groups, outperforming traditional assessment methods. METHODOLOGY: A multicenter (n = 49), prospective, observational clinical trial enrolled 1105 recipients of allogeneic hematopoietic cell transplantation aged ≥ 60 years (range, 60-82 years) from centers across the US. Researchers analyzed associations between 13 measurements of older adult health and nonrelapse mortality within 1 year to construct a comprehensive health assessment risk model using multivariate Fine-Gray model and grouped penalized variable selection. Analysis included two machine learning models (Cox and pseudo-value boosting) for comparison, with performance evaluated using area under the curve, bootstrap and cross-validation sampling, decision curve analysis, calibration, and Brier scores. Primary outcome measure was 1-year nonrelapse mortality, defined as death without relapse or progression of primary hematologic malignancy. TAKEAWAY: Primary-CHARM identified seven key predictors: higher comorbidity burden, C-reactive protein, weight loss, and age, along with lower albumin, patient-reported performance score, and cognitive score (hazard ratio [HR], 2.72; P < .0001). Patients in low, intermediate, and high CHARM score tertiles showed 1-year nonrelapse mortality rates of 8.1% (95% CI, 5.6-11.1), 12.1% (95% CI, 9.1-15.7), and 23.3% (95% CI, 19.0-27.7), respectively. Overall survival at 1 year was 71.7% (95% CI, 68.2-75.1), with CHARM scores stratifying survival to 81.2%, 73.8%, and 59.6% for low, intermediate, and high-risk tertiles. CHARM demonstrated higher net benefit than HCT-comorbidity index across a wide range of threshold probabilities for nonrelapse mortality. IN PRACTICE: 'The CHARM should improve decision-making [and] selection of the best transplant strategy by weighing risks vs benefits, allow calibration of data across trials and institutions, and ensure that appropriate older patients are not excluded from curative-intent allo-HCT,' wrote the authors of the study. SOURCE: The study was led by Mohamed L. Sorror, PhD, Clinical Research Division, Fred Hutchinson Cancer Center in Seattle, Washington. It was published online in Blood Advances. LIMITATIONS: The researchers acknowledged that the cross-validation bias-corrected area under the curve of 0.591 for primary-CHARM was modest, indicating room for improvement in predictive accuracy. The study's large sample size requirement and declining nonrelapse mortality made a parallel external validation cohort impractical. Additionally, the contribution from underrepresented minority groups was modest despite broad eligibility and supporting three languages. The study was conducted only in US centers, potentially limiting its global applicability. DISCLOSURES: The study received support from grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute. Sorror reported receiving consultancy fees and honoraria from JAZZ Pharmaceuticals for educational talks and research funding from BlueNote. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
5 days ago
- Yahoo
Family's complaint to care home was ignored… days later their loved one suffered fatal fall
The tragic death of a vulnerable woman happened after a care home she was staying at ignored her family's concerns. The family of 73-year-old cancer sufferer Marion Jones checked her into a Greater Manchester care home for a respite stay earlier this year and made a complaint that bed rails were not fixed to her bed. Despite giving assurances that an assessment would be carried out, staff at Riverside Care Home in Hyde did not take any action. READ MORE: 'People don't see it as a real course - but we've turned down multiple job offers' READ MORE: Manchester mum on Cyprus holiday turns on fellow hotel guests Ms Jones fell from her bed on March 23 - three days after her family's complaint - and died 10 days later on April 2 as a result of traumatic brain injuries from her fall, as well as her Stage 4 lung cancer. Never miss a story with the MEN's daily Catch Up newsletter - get it in your inbox by signing up here Now, a coroner has said that the care home's failure to oblige to the family's wishes led to the fall that contributed to Ms Jones' death and has ordered the care home company Care UK to make changes to avoid further deaths in the future. Benjamin Myers, assistant coroner for Greater Manchester South, oversaw an inquest into Ms Jones' death. He said: 'The inquest heard that family members raised their concerns on admission of Marion Jones to Riverside when they saw there were no bed rails. 'They were assured that an assessment would take place. This did not happen: it should have done.' The coroner heard the medical cause of death was '1a traumatic brain injury, 1b fall, 1c squamous cell lung cancer with skin and brain metastases'. He added: 'Until January 2025, Marion Jones had led an active life. However, in January 2025, she was diagnosed with Stage 4 lung cancer accompanied by a decline in her physical and mental condition. The cancer was inoperable and untreatable. 'The care was to be palliative within the community. After being cared for by her family, she went into respite care at Willow Woods hospice and from there to Riverside care home. 'Marion Jones was unstable in her movement and required the assistance of one or two carers for most physical activities, including getting in and out of bed. 'At Willow Wood, Marion Jones's bed had been fitted with bed rails. Prior to being admitted to Riverside, a pre-admission assessment was conducted by staff from Riverside. 'Although the relevant pre-admission form contains a section for assessment of safety equipment such as bed rails, no such assessment is recorded. 'Bed rails were not fitted to Marion Jones's bed at Riverside. Her family raised complaint about this on her admission to Riverside on 20th March 2025. 'They were assured that an assessment for bed rails would take place. No assessment did take place and on the 23rd March 2025 Marion Jones fell from her bed, which had not been fitted with rails. 'She landed on the floor, banging her head which caused visible injury, and which contributed to and hastened her physical and mental decline. 'The bed had been lowered but no crash mat had been put in place, contrary to the acknowledged requirement to do this. Had bed rails been in place this fall would not have happened.' Dave Ankers, Care UK's regional director for the North West, gave a statement to the Manchester Evening News saying on the day of Ms Jones' fall, key policies were not being followed. Join the Manchester Evening News WhatsApp group HERE He said: 'Care UK is dedicated to ensuring residents receive kind and considerate person-centred care. 'On the day in question, key policies were not being followed and as a result, the care Mrs Jones received did not meet our expectations. We have learned from this sad incident and made a number of significant changes to ensure it is not repeated. This includes reviews and updates to training, policies, and recording sheets, which we will be sharing across all of our care homes. 'We will continue to address the points raised and are now in the process of responding to the report from HM Coroner.' The coroner has written to Andrew Knight, the Chief Executive of Care UK, asking for action to be taken in order to prevent further deaths in similar circumstances in the future. He said the inquest also heard that previous incidents had occurred where bed rails had not been in place.
